LEN vs NBY · rev $14.56B vs $51.9M cap
LEN (LEN) versus NovaBay Pharmaceuticals Inc (NBY) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
NovaBay Pharmaceuticals Inc (NBY) is a biotechnology company listed on US.
Latest reported LEN revenue for 2026-05-31 was $14.56B. Net income was $534.2M. LEN currently screens at market cap $0.
NBY does not have a complete income-statement cache yet.
LEN currently screens at market cap $0. NBY currently screens at market cap $51.9M.
Not investment advice. Open the LEN and NBY stock pages for the full models.
Not investment advice.